Why Regeneron Pharmaceuticals, Inc. (REGN) stock moved
Updated Aug 31, 2026
Regeneron Pharmaceuticals, Inc. (REGN) shares rose 0.6% to $799.08 as of August 31, 2026, a slight gain from the prior close of $794.19. BestStocks flagged the session as a major change for REGN. Below, we break down what changed for REGN, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
REGN climbed 0.6% to $799.08
REGN rose 0.6% in its latest session, moving from $794.19 to $799.08.
ValuationWeak confidence
Rel. volume
1.0×
Below Avg
Vs peers
—
No comparable peers
Market cap
$82.3B
NASDAQ Global Select
Analyst target
$821
+2.7% vs price
Price chart
Jul 31 – Aug 31
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Regeneron Pharmaceuticals, Inc. investors
For Regeneron Pharmaceuticals, Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Positive 0.6% session move. Weighing against that: Regeneron Pharmaceuticals, Inc. (REGN) moved -3.56% from $675.19 to $651.18 on 2026-07-22; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $820.65, implying +2.7% upside from $799.08. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality weak (36/100). With earnings roughly 58 days out, the next report is the most likely near-term test of the move.
REGN price reaction
REGN last traded at $799.08, up $4.89 (+0.62%) from the previous close of $794.19. The session traded on 1.0× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $759.24 and $840.84, and it currently sits about 49% of the way up that band.
Bullish and bearish analyst opinions on Regeneron Pharmaceuticals, Inc. (REGN)
The consensus analyst price target on Regeneron Pharmaceuticals, Inc. (REGN) is $820.65, 2.7% above the recent $799.08. Over the past 90 days analysts logged 1 upgrade, 15 maintains, and 0 downgrades. Here is how the bullish and bearish cases on REGN line up.
▲ The bullish case
+Wall Street's consensus price target of $820.65 implies +2.7% upside from $799.08.
+The Street's most bullish target is $1,030.00 (+28.9%).
+1 analyst upgrade in the past 90 days, most recently Benchmark to Buy (2026-07-07).
+Material positive event.
+Positive 0.6% session move.
▼ The bearish case
−The most bearish analyst target is $730.00 (-8.6%).
−Regeneron Pharmaceuticals, Inc. (REGN) moved -3.56% from $675.19 to $651.18 on 2026-07-22.
Bull vs bear balanceBullish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Aug 31, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Regeneron Pharmaceuticals rose 2.15% to $844.45 following FDA approval of Pasatru (garetosmab-grts) for fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru is the first and only approved treatment for FOP and demonstrated efficacy in reducing new bone lesions and clinician-assessed flare-ups in clinical trials. The move also reflects continued momentum from the company's Q2 results and pipeline updates.
Material / Earnings2026-08-18+0.5%
Regeneron Pharmaceuticals, Inc. (REGN) moved -0.46% from $814.00 to $810.24 on 2026-08-18. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The stock reached a new 30-day high at the closing price, and volume remained near its 5-day average.
Regeneron extended gains driven by continued investor digestion of a strong Q2 earnings beat ($14.29 EPS vs. $10.16 consensus) and robust demand for core products Eylea HD and Dupixent, per the web catalyst. The stock rose 2.11% to $814.83 on solid institutional buying, though volume of 229,835 shares (0.53x expected at this time of day) remained below average.
REGN rose 2.35% to $802.81, buoyed by positive momentum from strong Q2 results and upward earnings revisions. According to the web catalyst synthesis, robust sales of flagship products Dupixent and Eylea HD, combined with Wall Street's steady increase in full-year consensus earnings estimates, have supported the move. An upcoming dividend of $0.94 (ex-date August 18, 2026) and the company's active share buyback program further underpin investor confidence.
Material / Earnings2026-08-07+1.6%
Regeneron Pharmaceuticals, Inc. (REGN) moved +1.28% from $774.47 to $784.36 on 2026-08-07, reaching a new 30-day high.
Material / Earnings2026-08-06+0.5%
REGN moved -0.74% from its $777.85 open to a $772.11 close on 2026-08-06.
Regeneron beat Q2 earnings expectations decisively, reporting non-GAAP EPS of $14.29 versus consensus of ~$10.16, and grew revenue 16.7% year-over-year to $4.29 billion, per the earnings report filed today. Key franchises drove the beat: Dupixent (partner Sanofi) rose 38% to $6.0B, EYLEA HD jumped 52% to $596M, and Libtayo climbed 30% to $489M. Management also raised full-year gross margin guidance to 78–79% (GAAP) and 84–85% (non-GAAP). Volume at 507k shares (0.92x average) is normal for this point in the session.
Material / Earnings2026-07-30+6.2%
Regeneron Pharmaceuticals, Inc. (REGN) reported EPS of $14.29 vs. consensus estimate of $10.16, beating estimates by 40.6% for Q2 FY2026.
Upcoming catalysts & outlook
Next earnings
2026-10-28 (est.)
in 58 days
10-Q Filing (est.)
2026-10-29
Medium impact
Thesis shift
Bullish Shift
bullish signal
Risk level
Medium
from change events
Frequently asked questions about REGN
Why did Regeneron Pharmaceuticals, Inc. (REGN) stock move?
REGN rose 0.6% to $799.08. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did REGN stock rise?
REGN gained 0.62% ($4.89) versus the prior close of $794.19, last trading at $799.08 on 1.0× average volume.
When is Regeneron Pharmaceuticals, Inc.'s next earnings date?
REGN's next earnings report is estimated for 2026-10-28 — about 58 days away.
What is the analyst price target for REGN?
The consensus analyst price target for REGN is $820.65, about 2.7% above the current $799.08. Over the past 90 days, analysts recorded 1 upgrade, 15 maintains, and 0 downgrades.
How BestStocks tracks REGN
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared REGN-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for REGN, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of August 31, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
